.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Moodys
Citi
Chubb
Fish and Richardson
Express Scripts
Federal Trade Commission
Queensland Health
Fuji
Argus Health

Generated: June 28, 2017

DrugPatentWatch Database Preview

OVIDREL Drug Profile

« Back to Dashboard

What is the patent landscape for Ovidrel, and what generic Ovidrel alternatives are available?

Ovidrel is a drug marketed by Emd Serono and is included in one NDA. There is one patent protecting this drug.

This drug has seventeen patent family members in fourteen countries.

The generic ingredient in OVIDREL is choriogonadotropin alfa. One supplier is listed for this compound. Additional details are available on the choriogonadotropin alfa profile page.

Summary for Tradename: OVIDREL

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list22
Drug Prices:see details
DailyMed Link:OVIDREL at DailyMed

Pharmacology for Tradename: OVIDREL

Ingredient-typeGonadotropins
Drug ClassGonadotropin
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emd Serono
OVIDREL
choriogonadotropin alfa
INJECTABLE;INJECTION021149-001Sep 20, 2000DISCNNoNo► Subscribe► Subscribe
Emd Serono
OVIDREL
choriogonadotropin alfa
INJECTABLE;SUBCUTANEOUS021149-002Oct 6, 2003RXYesYes6,706,681► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OVIDREL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Emd Serono
OVIDREL
choriogonadotropin alfa
INJECTABLE;INJECTION021149-001Sep 20, 20005,767,251► Subscribe
Emd Serono
OVIDREL
choriogonadotropin alfa
INJECTABLE;SUBCUTANEOUS021149-002Oct 6, 20035,767,251► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OVIDREL

Country Document Number Estimated Expiration
Portugal814841► Subscribe
Denmark0814841► Subscribe
Spain2166841► Subscribe
Brazil9510567► Subscribe
Australia2110695► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: OVIDREL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/030United Kingdom► SubscribePRODUCT NAME: RECOMBINANT CHORIOGONADOTROPIN ALFA; REGISTERED: UK EU/1/00/165/001-006 20010202
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Colorcon
Julphar
Harvard Business School
Novartis
Dow
Covington
Express Scripts
Argus Health
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot